@article{fb9535203d8f4d8b9b3b9c16665ff489,
title = "Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance",
keywords = "biomarker, breast cancer, CDK4/6, endocrine therapy, luminal, metastatic, prognosis, resistance, thymidine kinase-1, TK1",
author = "Amelia Mccartney and Luca Malorni",
note = "Funding Information: This work was partially supported by a grant from the Breast Cancer Research Foundation (grant number BCRF 19-037) and by a grant from Fondazione AIRC (IG 22869). L Malorni has received research support from Novartis and Pfizer and is a consultant for Eli Lilly, Pfizer and Novartis. Both authors have academically collaborated with Biovica International without any financial remuneration or contractual agreement. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart than those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2020",
month = may,
doi = "10.2217/bmm-2020-0072",
language = "English",
volume = "14",
pages = "495--498",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "7",
}
